CVS vs TXG · P/E 16, rev $402.07B vs rev $610.8M
CVS Health Corp (CVS) versus 10X Genomics Inc (TXG) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. TXG currently screens at market cap $4.08B.
Not investment advice. Open the CVS and TXG stock pages for the full models.
Not investment advice.